KYKen Yoshida

Ken Yoshida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ken Yoshida has a total of 104 co-authors. Here are the top co-authors by number of shared publications:

  • Daitaro Kurosaka

    Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Japan

    16 shared publications
  • Haruyasu Ito

    Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine , Tokyo

    6 shared publications
  • Kentaro Noda

    Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan

    6 shared publications
  • Kentaro Noda

    Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan

    5 shared publications
  • Daitaro Kurosaka

    Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-8461, Japan

    4 shared publications
  • Isamu Kingetsu

    Jikei University School of Medicine Tokyo Japan

    4 shared publications

Latest Publications

  • Open Access

    Multicenter Clinical Comparison Between Anti‐ NXP2 and Anti‐ TIF1 ‐γ Antibody‐Positive Myositis, and Analysis of the Clinical Significance of Anti‐ NXP2 Antibody Titers in Idiopathic Inflammatory Myopathies

    by Satoshi Kamiya, Mariko Ogawa‐Momohara, Yoshinao Muro, Yuta Yamashita, Satoko Yuasa, Masato Kakeda, Kimiko Nakajima, Hiroyuki Morita, Mitsuyo Kinjo, Takako Hashimoto, et al.

    We aimed to measure anti‐nuclear matrix protein 2 antibody (anti‐NXP2) titers in patients with anti‐NXP2‐positive idiopathic inflammatory myopathies, investigate whether these titers are associated with clinical manifestations, malignancy risk, and treatment response, and compare the clinical and serological features between anti‐NXP2‐positive and anti‐transcriptional intermediary factor 1‐γ antibody (anti‐TIF1‐γ)‐positive dermatomyositis in order to identify practical indicators for differentiating the two subsets. We established a newly optimized in‐house enzyme‐linked immunosorbent assay for the quantitative measurement of anti‐NXP2. After excluding two of the 34 initially identified patients with anti‐NXP2 antibody reactivity, we used the assay to analyse sera from 32 patients with anti‐NXP2‐positive idiopathic inflammatory myopathy. Clinical correlations between anti‐NXP2 titers and inflammatory indices, cardiothoracic ratio, malignancy status, and longitudinal changes after immunosuppressive therapy were examined. We developed a novel clinical scoring system to differentiate between anti‐NXP2‐positive and anti‐TIF1‐γ‐positive myositis. The anti‐TIF1‐γ‐positive patients showed a higher frequency of classic dermatomyositis skin manifestations, whereas the anti‐NXP2‐positive patients had significantly higher creatine kinase, aldolase, and lactate dehydrogenase levels, indicating more prominent muscle involvement. Anti‐NXP2 titers correlated with erythrocyte sedimentation rate and cardiothoracic ratio and were significantly higher in patients with malignancy in the anti‐NXP2‐positive idiopathic inflammatory myopathy patients. Longitudinal analyses demonstrated declines in antibody titers after immunosuppressive treatment. Our scoring system, incorporating age at onset, Gottron's sign, creatine kinase, lactate dehydrogenase, and malignancy status, highly accurately distinguished between anti‐NXP2‐positive and anti‐TIF1‐γ‐positive myositis. Anti‐NXP2 titers reflect systemic inflammation, cardiac involvement, and malignancy risk in anti‐NXP2‐positive idiopathic inflammatory myopathy. The observed decline in anti‐NXP2 titers after therapy suggests the potential utility of these titers as biomarkers for longitudinal disease assessment and stratifying malignancy risk.

  • Open Access

    Lemierre's Syndrome with a Palmar Lesion

    by Masayori Moriyama, Ken Yoshida, Daitaro Kurosaka

    Lemierre's syndrome can be fatal if diagnosed late or not treated appropriately. We herein report a 40-year-old woman with a fever and pain with tenderness in her palms after the administration of antibiotics for pharyngotonsillitis. She was diagnosed with Lemierre's syndrome, and her symptoms improved after the administration of intravenous ampicillin-sulbactam. In this case, the palmar lesions indicated septic emboli and were an important finding in recognizing Lemierre's syndrome. Lemierre's syndrome should be considered in the differential diagnosis of patients with a persistent fever following oropharyngeal infection, even if they have received antimicrobial therapy, resolved pharyngeal symptoms, and negative culture results.


  • A case of adult-onset Still disease with eyelid xanthogranuloma mimicking Erdheim–Chester disease

    by Keigo Hirafuku, Masahiro Kanbe, Itaru Dekio, Ken Yoshida, Daitaro Kurosaka, Akira Honda, Mineo Kurokawa, Akihiko Asahina

    We report an exceptionally rare but interesting case of adult-onset Still disease (AOSD) accompanied by large xanthogranuloma of the eyelid in a patient who had symptoms reminiscent of Erdheim–Chester disease (ECD). The symptoms of AOSD and ECD overlap; therefore, we believe it is important to remind clinicians that when xanthogranuloma occurs in a patient with AOSD, the possibility of ECD should be considered.

  • Magnetic resonance imaging patterns revealing muscle pathology and clinical features in idiopathic inflammatory myopathies

    by Takashi Shimoyama, Ken Yoshida, Yoshinao Muro, Haruyasu Ito, Takayuki Matsushita, Yohsuke Oto, Taro Ukichi, Kentaro Noda, Daitaro Kurosaka

    Idiopathic inflammatory myopathies (IIMs) are autoimmune disorders significantly impacting skeletal muscles; however, the precise correlation between muscle magnetic resonance imaging (MRI) findings, muscle pathology, disease subtypes, and clinical characteristics remains uncertain. Thus, we investigated the association of muscle MRI findings in IIMs with muscle pathology and clinical features. New-onset IIM patients underwent proximal upper and/or lower limb muscle MRI. Patterns of muscle oedema on MRI were categorised into fascial, honeycomb, peripheral, foggy, dense, or coarse dot patterns and compared with inflammatory cell infiltration sites in corresponding muscle biopsies. The incidence of MRI patterns was examined in patient subgroups using myositis-specific antibodies (MSAs) and 2017 EULAR/ACR classification criteria. Univariate and multivariate analyses were conducted to determine the odds ratios (ORs) of MRI findings for clinical characteristics. Fifty-six of 85 patients underwent muscle biopsy. Foggy, honeycomb, and fascial patterns at biopsy sites correlated with inflammatory cell infiltration in the endomysium (OR 11.9, p= 0.005), perimysium (OR 6.0, p= 0.014), and fascia (OR 16.9, p< 0.001), respectively. Honeycomb and foggy patterns were characteristic of patients with anti-TIF1γ or anti-Mi2 antibodies and MSA-negative dermatomyositis, and those with anti-SRP or anti-HMGCR antibodies and MSA-negative polymyositis (PM), respectively. The honeycomb pattern positively correlated with malignancy (OR 6.87, p< 0.001) and Gottron sign (OR 8.05, p= 0.002); the foggy pattern correlated with muscle weakness (OR 11.24, p= 0.005). The dense dot pattern was associated with dysphagia (OR 6.27, p= 0.006) and malignancy (OR 8.49, p= 0.002). Muscle MRI holds promise in predicting muscle pathology, disease subtypes, and clinical manifestations of IIMs.


  • Open Access

    Intramuscular lesions in musculoskeletal MRI as a favourable prognostic sign in patients with anti-MDA5 antibody-positive dermatomyositis

    by Yohsuke Oto, Ken Yoshida, Takeshi Fukuda, Taiki Fukuda, Taro Ukichi, Kentaro Noda, Haruyasu Ito, Daitaro Kurosaka

    Objectives Anti-differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis, which has been described as clinically amyopathic dermatomyositis, complicates rapidly progressive interstitial lung disease (ILD). Owing to the absence of significant muscle symptoms, musculoskeletal MRI is often not performed. In this study, we aimed to devise a simple evaluation method using musculoskeletal MRI findings to elucidate the relationship between MRI findings and ILD prognosis and development. Methods The medical records and MRI scans of the proximal muscles at the time of diagnosis were retrospectively reviewed for 28 patients with anti-MDA5 antibody-positive dermatomyositis who were admitted to The Jikei University Hospital and The Jikei University Kashiwa Hospital between January 2008 and March 2022. Three observers evaluated nine proximal muscles for high signals on either short-tau inversion recovery images and/or fat-saturated gadolinium-enhanced T1-weighted images in the fascia and/or in the margins of the muscles in contact with the fascia (fascial pattern), and/or high signals in the muscles away from the fascia (intramuscular pattern), and a consensus was reached. Results Of the 28 patients, 15 presented with ‘radiological myositis’, where an intramuscular pattern was observed at any site. Patients with radiological myositis had significantly higher survival rates than those without radiological myositis, despite the lower rate of triple therapy with prednisolone, calcineurin inhibitors and cyclophosphamide. The spread of ILD on chest CT negatively and significantly correlated with the proportion of intramuscular lesions. Conclusion The detection of intramuscular lesions on musculoskeletal MRI using our novel evaluation method could be clinically useful as a favourable prognostic marker.


  • Open Access

    Autocitrullination confers monocyte chemotactic properties to peptidylarginine deiminase 4

    by Ken Yoshida, Haruyasu Ito, Daisaburo Kurosaka, Ryo Ikeda, Kentaro Noda, Mitsuru Saito, Daitaro Kurosaka

    Peptidylarginine deiminase 4 (PAD4) contributes to the production of citrullinated proteins as autoantigens for anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA). PAD4 can also self-deiminate via autocitrullination. However, the role of this process in RA pathogenesis has not been elucidated. This study aimed to clarify PAD4 function before and after autocitrullination and identify citrullinated PAD4 in the synovial fluid of patients with RA. The autocitrullination of recombinant human PAD4 (rhPAD4) was catalyzed in vitro and determined using anti-modified citrulline immunoblotting. Monocyte chemotaxis was evaluated using Boyden chambers, and citrullinated rhPAD4’s ability to induce arthritis was assessed in a C57BL/6J mouse model. Citrullinated PAD4 levels were measured in the synovial fluid of patients with RA and osteoarthritis using a novel enzyme-linked immunosorbent assay. Chemotactic findings showed that citrullinated rhPAD4 recruited monocytes in vitro, whereas unmodified rhPAD4 did not. Compared to unmodified rhPAD4, citrullinated rhPAD4 induced greater inflammation in mouse joints through monocyte migration. More citrullinated PAD4 was found in the synovial fluid of patients with RA than in those with osteoarthritis. Citrullinated PAD4 was even detected in ACPA-negative patients with RA. The autocitrullination of PAD4 amplified inflammatory arthritis through monocyte recruitment, suggesting an ACPA-independent role of PAD4 in RA pathogenesis.


  • Open Access

    Transcriptome Profiling of Immune Cell Types in Peripheral Blood Reveals Common and Specific Pathways Involved in the Pathogenesis of Myositis‐Specific Antibody‐Positive Inflammatory Myopathies

    by Yusuke Sugimori, Yukiko Iwasaki, Yusuke Takeshima, Mai Okubo, Satomi Kobayashi, Hiroaki Hatano, Saeko Yamada, Masahiro Nakano, Ryochi Yoshida, Mineto Ota, et al.

    Objective: Idiopathic inflammatory myopathies (IIM) demonstrate characteristic clinical phenotypes depending on the myositis‐specific antibody (MSAs) present. We aimed to identify common or MSA‐specific immunological pathways in different immune cell types from peripheral blood by transcriptome analysis.Methods: We recruited 33 patients with IIM who were separated into the following groups: 15 patients with active disease at onset and 18 with inactive disease under treatment. All patients were positive for MSAs: anti–melanoma differentiation‐associated gene 5 (MDA5) antibody (Ab) in 10 patients, anti‐Mi‐2 Ab in 7, and anti‐aminoacyl‐transfer RNA synthetase (ARS) Ab in 16. The patients were compared with 33 healthy controls. Twenty‐four immune cell types sorted from peripheral blood were analyzed by flow cytometry, RNA sequencing, and differentially expressed gene analysis combined with pathway analysis.Results: The frequencies of memory B cell types were significantly decreased in active patients, and the frequency of plasmablasts was prominently increased in active patients with anti‐MDA5 Ab in comparison with healthy controls. The expression of type I interferon (IFN)‐stimulated genes of all immune cell types was increased in the active, but not inactive, patients. Endoplasmic reticulum stress‐related genes in all IIM memory B cells and oxidative phosphorylation‐related genes in inactive IIM double negative B cells were also increased, suggesting prominent B cell activation in IIM. Furthermore, active patients with anti‐MDA5 Ab, anti‐Mi‐2 Ab, or anti‐ARS Ab were distinguished by IFN‐stimulated and oxidative phosphorylation‐related gene expression in plasmablasts.Conclusion: Unique gene expression patterns in patients with IIM with different disease activity levels and MSA types suggest different pathophysiologies. Especially, B cells may contribute to common and MSA‐specific immunological pathways in IIM.


  • Open Access

    Mammalian Glycosylation Patterns Protect Citrullinated Chemokine MCP-1/CCL2 from Partial Degradation

    by Olexandr Korchynskyi, Ken Yoshida, Nataliia Korchynska, Justyna Czarnik-Kwaśniak, Paul P. Tak, Ger J. M. Pruijn, Takeo Isozaki, Jeffrey H. Ruth, Phillip L. Campbell, M. Asif Amin, et al.

    Monocyte chemoattractant protein-1 (MCP-1/CCL2) is a potent chemotactic agent for monocytes, primarily produced by macrophages and endothelial cells. Significantly elevated levels of MCP-1/CCL2 were found in synovial fluids of patients with rheumatoid arthritis (RA), compared to osteoarthritis or other arthritis patients. Several studies suggested an important role for MCP-1 in the massive inflammation at the damaged joint, in part due to its chemotactic and angiogenic effects. It is a known fact that the post-translational modifications (PTMs) of proteins have a significant impact on their properties. In mammals, arginine residues within proteins can be converted into citrulline by peptidylarginine deiminase (PAD) enzymes. Anti-citrullinated protein antibodies (ACPA), recognizing these PTMs, have become a hallmark for rheumatoid arthritis (RA) and other autoimmune diseases and are important in diagnostics and prognosis. In previous studies, we found that citrullination converts the neutrophil attracting chemokine neutrophil-activating peptide 78 (ENA-78) into a potent macrophage chemoattractant. Here we report that both commercially available and recombinant bacterially produced MCP-1/CCL2 are rapidly (partially) degraded upon in vitro citrullination. However, properly glycosylated MCP-1/CCL2 produced by mammalian cells is protected against degradation during efficient citrullination. Site-directed mutagenesis of the potential glycosylation site at the asparagine-14 residue within human MCP-1 revealed lower expression levels in mammalian expression systems. The glycosylation-mediated recombinant chemokine stabilization allows the production of citrullinated MCP-1/CCL2, which can be effectively used to calibrate crucial assays, such as modified ELISAs.